Colorectal cancer is the leading cause of death from digestive disease, with more than 145,000 new cases detected in the USA annually. More than 1 Mio worldwide each year.

In our last blog entry you had the opportunity to read AND download our annual newsletter 2015. We stated that we expect more instruments to broaden the pipeline of new products of the Endolumenal Surgical Platform (ESP) to be used for educational purposes until regulatory approval.

Today we bring you our first news for 2016. Here we focus on our new brochure that we would like to show you. In the brochure. we explain in layman’s language how minimally-invasive surgery works. Particular focus is on performing surgery inside the intestine.

1. Endoluminal Surgical Platform (ESP)

This is a novel device for medical digestive disease therapy once we get regulator clearance.. As the brochure below outlines:

Colorectal cancer is the leading cause of death from digestive disease. Worldwide, more than 1 million new cases are being detected each year.

Up to 40% of all polyps (precancerous growths) are missed during standard colonoscopies.


2. Three benefits

Digestive diseases become prevalent in patients after the age of 50. It increases rapidly in mean and women after age 65. Accordingly, as the population ages, the cost of providing good care is also increasing.


You can get more detail about these and other issues in our brochure below. If you wish to view the brochure from Cornell University, drop us a line in a comment below.

The brochure is outdated, so it was taken off.

Join the discussion

–  Do you have a question about Lumendi or its technology, ask – we answer right here.

–  Have you or one of your friends experienced minimally-invasive surgery – what is their experience?

Of course, we will keep you posted with important information all throughout 2016. Just subscribe to our newsletter and stay informed!

Professor Urs E. Gattiker - DrKPI is corporate Europe's leading social media metrics expert (see his books). He continues to work with start-ups. Urs is CEO of CyTRAP Labs GmbH.

3 Thoughts on “3 benefits with minimally-invasive endolumenal surgery”

  • It’s a pretty simple breakdown of such a complicated process, but it’s no less true.

    The introduction of techniques like these, including laproscopic surgical procedures, has enabled surgeons to complete complicated surgeries in minimal time, and with faster recovery times than traditional techniques.

    Consult with your surgeon to see if minimally invasive surgery is the right option for your specific medical needs.

  • Thanks Andrew for this feedback.

    But of course, as you point out it depends on such things as:

    1. Does this represent a procedure that meets the patient’s specific medical needs, AND
    2. Getting FDA clearance to empower physicians and surgeons to use it.

    Thanks for sharing.

Leave a Reply

Your email address will not be published. Required fields are marked *